By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alexion Pharmaceuticals Inc. 

352 Knotter Drive

Cheshire  Connecticut  06410  U.S.A.
Phone: 203-272-ALXN Fax: 203-271-8198


Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.

Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.

Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.

Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).

Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.

Key Statistics

Ownership: Public

Web Site: Alexion
Employees: 1,500
Symbol: ALXN



Company News
Alexion (ALXN) Announces Presentations At 2015 American Transplant Congress, Including Results From Studies Advancing The Understanding Of Eculizumab (Soliris) In Patients Undergoing Kidney Transplant 4/13/2015 8:22:17 AM
Alexion (ALXN) Receives Approval For Important Updates To The European Label For Soliris (Eculizumab) 4/10/2015 11:44:11 AM
With Alexion (ALXN) Deal in Hand, Blueprint Medicines Preps for $100 Million IPO 3/24/2015 6:06:57 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: New Data From First Natural History Study In Juveniles With Hypophosphatasia (HPP) Showing Substantial Disease Burden, Including Musculoskeletal Abnormalities And Growth Deficiencies, Presented In Late-Breaking Oral Session At ENDO 2015 3/9/2015 11:38:35 AM
Blueprint Medicines Strikes $265 Million Deal With Alexion Pharmaceuticals Inc. (ALXN) 3/3/2015 7:26:15 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: FDA Grants Priority Review For Asfotase Alfa As A Treatment For Patients With Hypophosphatasia 3/2/2015 11:36:57 AM
Alexion Pharmaceuticals Inc. (ALXN) Joins Patient Organizations Worldwide In Support Of International Rare Disease Day 2015 2/27/2015 10:52:35 AM
Alexion Pharmaceuticals Inc. (ALXN) Receives CHMP Positive Opinions For Important Updates To The EU Label For Soliris (eculizumab) 2/27/2015 10:51:00 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: New Data From A Natural History Study In Patients With Infantile- And Juvenile-Onset Hypophosphatasia Accepted As Late-Breaking Abstracts At The ENDO 2015 Annual Meeting 2/9/2015 10:29:49 AM
Alexion Pharmaceuticals Inc. (ALXN) To Present At The 2015 Leerink Global Healthcare Conference 2/5/2015 12:00:50 PM